TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

BenevolentAI and AstraZeneca Collaborate on Groundbreaking Heart Failure Research, Identifying Novel Treatment Target

Thursday, May 16, 2024

BenevolentAI, a leader in utilizing advanced AI for accelerating biopharma drug discovery, has announced a significant development in its collaboration with AstraZeneca. Together, they have introduced a novel target for Heart Failure into AstraZeneca's research portfolio, leveraging BenevolentAI's AI-driven drug discovery platform.

This new target for Heart Failure was identified using BenevolentAI's platform and validated through experiments by AstraZeneca. It marks the first target to emerge from their expanded collaboration, demonstrating ongoing progress in Target Identification within the field.

The collaboration between BenevolentAI and AstraZeneca began in 2019, initially focusing on potential treatments for idiopathic pulmonary fibrosis (IPF) and chronic kidney disease (CKD). It was later expanded in January 2022 to include Heart Failure and Systemic Lupus Erythematosus (SLE), showcasing the versatility of Benevolent Platform™ across therapeutic domains.

This collaborative model combines the expertise of scientists and technologists from both organizations, integrating BenevolentAI's AI-driven drug discovery capabilities with AstraZeneca's scientific knowledge. The result is the discovery of novel therapeutic targets crucial for advancing drug development efforts. Both collaborations follow similar terms, including upfront payments, research funding, and potential milestone payments and royalties upon commercialization.

Heart Failure is a complex syndrome characterized by inadequate blood pumping by the heart, often with diverse underlying causes. Current treatments often overlook this heterogeneity. Therefore, the identification of new therapeutic avenues is essential due to the high mortality rate associated with Heart Failure.

BenevolentAI, expressed her satisfaction with AstraZeneca's selection of the novel Heart Failure target, emphasizing the collaborative effort needed to address medical needs in this critical area.

Regina Fritsche Danielson, SVP and Head of Research and Early Development, Cardiovascular, Renal, and Metabolism at AstraZeneca, praised the ongoing collaboration with BenevolentAI for uncovering insights into complex diseases like CKD and Heart Failure. She highlighted the potential of combining shared expertise with AI to pinpoint therapeutic targets tailored to patient needs, paving the way for innovative treatment modalities.

 

Source: businesswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit